How big is Psychemedics Corp.?

As of Jun 18, Psychemedics Corp. has a market capitalization of 15.25 million and reported net sales of 19.68 million with a net profit of -1.87 million over the latest four quarters.

Market Cap: As of Jun 18, Psychemedics Corp. has a market capitalization of 15.25 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Psychemedics Corp. reported net sales of 19.68 million and a net profit of -1.87 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 5.13 million and total assets of 8.83 million.

What does Psychemedics Corp. do?

Psychemedics Corp. specializes in hair testing for drug abuse and operates in the micro-cap market, with a market cap of $15.25 million and quarterly net sales of $4 million as of December 2024. The company currently reports no net profit and has a negative return on equity of -36.24%.

Overview:<BR>Psychemedics Corp. provides hair testing for drugs of abuse and operates in the miscellaneous industry within the micro-cap market.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4 Million (Quarterly Results - Dec 2024)<BR>- Net Profit: 0 Million (Quarterly Results - Dec 2024)<BR>- Market cap: USD 15.25 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.14<BR>- Return on Equity: -36.24%<BR>- Price to Book: 2.97<BR><BR>Contact Details:<BR>- Address: 125 Nagog Park Ste 200, ACTON MA: 01720-3451<BR>- Tel: 1 800 6288073<BR>- Fax: 1 302 6365454<BR>- Website: https://www.psychemedics.com/

Should I buy, sell or hold Psychemedics Corp.?

Who are in the management team of Psychemedics Corp.?

As of March 2022, the management team of Psychemedics Corp. includes Mr. Raymond Kubacki as Chairman, President, and CEO, along with independent directors Mr. A. Clinton Allen, Mr. Harry Connick, Mr. Walter Tomenson, and Mr. Fred Weinert.

As of March 2022, the management team of Psychemedics Corp. includes Mr. Raymond Kubacki, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features several independent directors: Mr. A. Clinton Allen, Mr. Harry Connick, Mr. Walter Tomenson, and Mr. Fred Weinert.

Is Psychemedics Corp. overvalued or undervalued?

As of March 29, 2022, Psychemedics Corp. is considered overvalued and risky due to poor financial metrics, a Price to Book Value of 2.93, an EV to EBITDA ratio of 14.29, and a one-year stock return of -8.88%, significantly underperforming compared to the S&P 500's 17.14% return.

As of 29 March 2022, the valuation grade for Psychemedics Corp. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued, given its negative performance metrics and ratios. The Price to Book Value stands at 2.93, while the EV to EBITDA ratio is 14.29, and the EV to Sales ratio is 0.73, all suggesting a lack of profitability and high valuation relative to sales.<BR><BR>In comparison to its peers, Psychemedics Corp. has a significantly lower EV to EBITDA ratio than Accolade, Inc. at -13.44 and Community Health Systems, Inc. at 8.02, indicating that it is struggling more than its competitors. Additionally, the company's recent stock performance has been poor, with a one-year return of -8.88%, compared to the S&P 500's return of 17.14%, reinforcing the notion that it is overvalued in the current market context.

Is Psychemedics Corp. technically bullish or bearish?

As of September 11, 2025, Psychemedics Corp. is in a mildly bearish trend, supported by bearish indicators and underperforming the S&P 500 with a year-to-date return of -5.63% compared to the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Psychemedics Corp. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and bearish signals from Dow Theory. The Bollinger Bands also indicate a mildly bearish trend on the weekly and a bearish trend on the monthly. <BR><BR>In terms of performance, Psychemedics has underperformed the S&P 500 across multiple periods, with a year-to-date return of -5.63% compared to the S&P 500's 12.22%, and a one-year return of -8.88% versus the S&P 500's 17.14%.